In 2016 alone, prescription opioids, heroin and synthetic opioids like fentanyl were responsible for more than 64,000 deaths. Fentanyl alone accounted for a 600 percent increase in opioid-related deaths between 2014 and 2016. In the journey to solve this epidemic, addiction researchers may have finally stumbled upon an answer that could one day save thousands of lives and slow down the tragedy eroding parts of the country–a vaccine that might inoculate the brain against drugs like heroin and other opioids.
While heroin and its prescription cousins, like Vicodin and oxycontin, are plenty addictive themselves, drug users have been turning to synthetic versions of these drugs that “can sometimes be as much as 100 times more potent than heroin,” said chemist Kim D. Janda of The Scripps Research Institute (TSRI) in California at a recent meeting of the American Chemical Society. Black market opiates are rumored to be as much as 10,000 times more powerful than morphine. “Moreover, many patients [are] receiving treatment relapse,” Janda added.
Despite the greater risks of overdose, these synthetics are cheaper and quicker to make and offer a greater high. But like all opioids, the longer one takes them, the more a person has to take in order to achieve the same effect until they are taking dangerously high amounts.
“There is an urgent need to discover effective medications to treat substance use disorders,” Janda said.
Drug treatment programs can be effective when people recognize they have a problem, and if they have the health insurance or finances to afford them. For many people in the grip of a substance abuse disorder, however, a simpler solution would be more effective and could save lives. This is where Janda’s vaccines come in.
While we generally associate vaccines with inoculation against bacteria and viruses, Janda, who has led several studies on these vaccines at TSRI, recently told Mental Floss, “There are ways to stimulate the immune response against different molecules besides bacterial pathogens or a virus.”
Janda and his team created tiny molecules known as haptens, small molecules that stimulate antibodies when they’re attached to a larger, “carrier” molecule. However, these molecules are so small the immune system doesn’t recognize them on their own, so they attached proteins called epitopes that allow antibodies produced by the immune system to bind to them.
To read more, please continue to page 2.
Once the immune system has been “trained” through a series of vaccination shots, it will react to any molecular structures that look like opioids and secrete antibodies that hitch a ride on drug molecules. This prevent them from permeating the blood-brain barrier for as long as eight months.
“The antibody binds to the drug so the drug can’t get to the target,” Janda explained.
Janda made clear that these vaccines don’t cure a drug addiction. “You’re not going to be giving these to kids or people who don’t do drugs,” he says. “This is for people who have problems getting off the drugs, [who] have issues with abstinence, which all addicts have.”
The most likely candidates for these vaccines will be people who have a history of overdoses or unsuccessful attempts to quit the drugs. Phil Skolnick, director of the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, which funded Janda’s work (as well as other similar research), said, “Getting [addicts] to make one good decision every day not to take opiates is a very tough thing to do.” By taking a biologic vaccine, as immune-based therapies are called, targeted to the drug they’re addicted to, “an addicted—and now immunized—person would have an enduring protection. That’s one of the strongest arguments for developing biologics against drugs of abuse,” he said.
Even more crucial, this vaccine has the potential to reduce overdose deaths; the receptors in the brain that give the “pleasure” part of a drug high are the same ones that can slow breathing when a person takes a high dose of the drug. With the vaccine in a person’s system, there’s a better chance even in amounts high enough to induce overdose, a person’s breathing won’t be affected.
While the research is promising, so far these studies, while promising, have only been tested on mice and monkeys. Researchers hope to be able to take them to human clinical trials before long.
“Vaccines are meant to be used by people who want to quit taking drugs,” Janda explained to Philip Ball at The Guardian.
“If you don’t want to stop then nothing will help. The idea is that if they have a moment of weakness, they won’t relapse and can continue with their therapy.”